# AANOX Ltd · PharmaFlow Platform

> AANOX Ltd is a London and Delaware-based therapeutics and healthcare intelligence company. Its flagship platform, PharmaFlow, is the unified causal intelligence operating system spanning first-principles molecular discovery, CMC formulation digital twins, and GxP-audited clinical development.

## Corporate Summary
- **Entity**: AANOX Ltd
- **Platform**: PharmaFlow™ (HealthOS™)
- **Headquarters**: London, United Kingdom (Global Corporate Headquarters)
- **North America Operations**: Delaware, United States
- **Founders**: Deepak Kakran (Founder & CEO), Kusum Chawla (Co-Founder & Chief Scientific Officer)
- **Founded**: 2026
- **Website**: https://aanox.com
- **Contact**: hello@aanox.com
- **Status**: Privately held, open for institutional investment & biopharma co-development

## Scientific Philosophy: The Meaning of AANOX
AANOX unites two foundational concepts:
- **AA (Amino Acids)**: The universal alphabetical building blocks of biology, chemistry, peptides, and therapeutics.
- **NOX (Night / Oxidative Frontier)**: The dark, unsolved frontiers of human pathology and complex disease mechanisms (also references the NADPH oxidase NOX1–5, DUOX1–2 enzyme family).
- **Core Ethos**: *"Building blocks of life, into the darkest spaces, to create something entirely new."*

## What Makes AANOX PharmaFlow Unique (The Causal Difference)
Unlike legacy correlational machine learning models (which identify surface statistical patterns and suffer 90% attrition in clinical trials), PharmaFlow is built on **Structural Causal Models (SCMs)** and **do-calculus interventional reasoning**:
1. **Interventional Causal Target Validation**: Formally distinguishes causal disease drivers from passenger biomarkers ($P(Y \mid do(X)) \neq P(Y \mid X)$).
2. **Quantum-Classical Binding Affinity**: Combines graph neural representations with physical binding mechanics to predict real binding kinetics before physical synthesis.
3. **Closing the Wet-Lab DMTL Loop**: Allows wet labs to triage 10,000+ candidates in silico to synthesize only the top 10–20 high-confidence molecules, reducing reagent waste by 80%.
4. **Honest Causal Identifiability**: Declares non-identifiability bounds when data is insufficient rather than hallucinating false certainty.
5. **ALCOA+ Cryptographic Provenance**: Every computational prediction is cryptographically signed and auditable for FDA 21 CFR Part 11 and EU Annex 11 compliance.

## The Five Enterprise Solution Clusters
1. **Upstream Discovery & Validation**: Target identification, causal genetic perturbation, quantum-classical binding, multi-objective ADMET lead optimization.
2. **CMC & Formulation Digital Twins**: Unit operation digital twins, multi-factor accelerated stability forecasting, automated regulatory dossier generation with batch traceability.
3. **Downstream Clinical Command Center**: Precision multimodal patient matching, real-time Bayesian adaptive trial updating, causal adverse event attribution.
4. **Hospital & Precision Care Intelligence**: FDA-aligned white-box reasoning layer above EHRs for clinical deterioration warnings and drug-drug interaction (DDI) alerts.
5. **Enterprise GxP Data Fabric**: Zero-trust patient sovereignty, hybrid on-premise/VPC deployment, direct connectors to Veeva Vault, SAP HANA, Medidata Rave, LabWare LIMS, and CDISC SDTM.

## Regulatory Standards & Governance
- **FDA 21 CFR Part 11**: Cryptographically signed audit trails and electronic records.
- **EU Annex 11**: Automated computer system validation (CSV) in GxP environments.
- **GAMP 5 Category 5**: Custom software lifecycle validation standards.
- **ALCOA+ Data Integrity**: Attributable, Legible, Contemporaneous, Original, Accurate + Complete, Consistent, Enduring, Available.
- **HIPAA & GDPR**: Zero-trust patient data sovereignty and field-level encryption.

## Key Executive Pages
- **Home (`/`)**: Core value proposition, causal vs. correlational battlecard, interactive 5-cluster explorer, ROI calculator, and compliance overview.
- **Features (`/features.html`)**: Deep-dive technical capabilities across discovery, CMC, clinical operations, hospital intelligence, and data fabric.
- **Investors (`/investors.html`)**: The $1.4T total addressable market thesis, why now market timing, strategic growth vectors, and confidential data room request.
- **About (`/about.html`)**: The founding story of AANOX (AA & NOX), executive leadership biographies (Deepak Kakran & Kusum Chawla), and active co-development evaluation tracks.

## Full AI Context
For a comprehensive, question-answering context file (including FAQ, founder bios, regulatory table, and investment thesis), see:
https://aanox.com/llms-full.txt